SABS SAB Biotherapeutics, Inc. - Common Stock
NASDAQ · Biotechnology close Oct 2, 2026
$2.98
· of 52w range
· above low
· to high
$2.0652w low
$5.1552w high
your badges
52W Range
$2–$5
Analyst Rating
BUY
Price Target
$12
P/E
·
ROE
·
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
SABS Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$2.98
52W Range
$2–$5
SABS Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| Jan. 5, 2024 | 1-for-10 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-5.7%
Next Report
Nov 11, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 5, 2026 | $-0.28 | $-0.30 | 5.1% |
| March 31, 2026 | May 7, 2026 | $-0.35 | $-0.23 | -50.3% |
| Dec. 31, 2025 | $-0.35 | $-0.20 | -72.7% | |
| Sept. 30, 2025 | $-0.15 | $-0.52 | 70.9% | |
| June 30, 2025 | $-1.09 | $-0.81 | -34.3% | |
| March 31, 2025 | $-0.56 | $-1.05 | 46.7% |
Institutional owners (13F) 92 filers · $275.0M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
92
Value held
$275.0M
New positions
33
Exited positions
20
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 33 (-8 vs prior Q) | 20 (+15 vs prior Q) | 27 (+5 vs prior Q) | 17 (+11 vs prior Q) | +1.7M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Caligan Partners LP | $31,072,107 | 7,967,207 | 11.30% | Shares |
| Vivo Capital, LLC | $28,469,645 | 7,299,909 | 10.35% | Shares |
| PERCEPTIVE ADVISORS LLC | $25,847,254 | 6,627,501 | 9.40% | Shares |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $24,981,657 | 6,405,553 | 9.09% | Shares |
| RA CAPITAL MANAGEMENT, L.P. | $17,165,850 | 4,401,500 | 6.24% | Shares |
| Balyasny Asset Management L.P. | $14,665,712 | 3,760,439 | 5.33% | Shares |
| BlackRock, Inc. | $11,957,462 | 3,066,016 | 4.35% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $11,594,423 | 2,972,929 | 4.22% | Shares |
| Commodore Capital LP | $11,193,000 | 2,870,000 | 4.07% | Shares |
| MILLENNIUM MANAGEMENT LLC | $10,721,439 | 2,749,087 | 3.90% | Shares |
| Spruce Street Capital LP | $8,574,158 | 2,198,502 | 3.12% | Shares |
| Sessa Capital IM, L.P. | $8,573,982 | 2,198,457 | 3.12% | Shares |
| VANGUARD GROUP INC | $6,908,288 | 1,847,136 | 2.51% | Shares |
| Affinity Asset Advisors, LLC | $5,947,500 | 1,525,000 | 2.16% | Shares |
| BOOTHBAY FUND MANAGEMENT, LLC | $5,778,474 | 1,481,660 | 2.10% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $4,981,704 | 1,277,185 | 1.81% | Shares |
| Woodline Partners LP | $4,603,385 | 1,180,355 | 1.67% | Shares |
| Ensign Peak Advisors, Inc | $4,573,300 | 1,172,641 | 1.66% | Shares |
| Propel Bio Management, LLC | $4,198,654 | 1,076,578 | 1.53% | Shares |
| Soleus Capital Management, L.P. | $3,510,000 | 900,000 | 1.28% | Shares |
| Seven Fleet Capital Management LP | $2,870,700 | 736,077 | 1.04% | Shares |
| AMERIPRISE FINANCIAL INC | $2,382,975 | 611,019 | 0.87% | Shares |
| STATE STREET CORP | $2,070,241 | 530,831 | 0.75% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,710,209 | 438,515 | 0.62% | Shares |
| DV EQUITIES, LLC | $1,560,000 | 400,000 | 0.57% | Shares |
| AWM Investment Company, Inc. | $1,462,500 | 375,000 | 0.53% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $1,458,522 | 373,980 | 0.53% | Shares |
| UBS Group AG | $1,426,924 | 365,878 | 0.52% | Shares |
| NORTHERN TRUST CORP | $1,413,707 | 362,489 | 0.51% | Shares |
| STEMPOINT CAPITAL LP | $1,336,261 | 342,631 | 0.49% | Shares |
| HB Wealth Management, LLC | $1,199,250 | 307,500 | 0.44% | Shares |
| Polymer Capital Management (HK) LTD | $1,195,666 | 306,581 | 0.43% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1,141,639 | 292,728 | 0.42% | Shares |
| JANE STREET GROUP, LLC | $883,350 | 226,500 | 0.32% | Put option |
| TWO SIGMA INVESTMENTS, LP | $837,065 | 214,632 | 0.30% | Shares |
| GOLDMAN SACHS GROUP INC | $746,089 | 191,305 | 0.27% | Shares |
| Bank of New York Mellon Corp | $420,604 | 107,847 | 0.15% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $412,160 | 105,682 | 0.15% | Shares |
| Simplify Asset Management Inc. | $408,911 | 104,849 | 0.15% | Shares |
| AMERICAN CENTURY COMPANIES INC | $330,271 | 84,685 | 0.12% | Shares |
| CITADEL ADVISORS LLC | $315,900 | 81,000 | 0.11% | Call option |
| ALPS ADVISORS INC | $302,640 | 77,600 | 0.11% | Shares |
| Stonepine Capital Management, LLC | $285,757 | 73,271 | 0.10% | Shares |
| CITADEL ADVISORS LLC | $244,908 | 62,797 | 0.09% | Shares |
| Nuveen, LLC | $227,752 | 58,398 | 0.08% | Shares |
| JANE STREET GROUP, LLC | $209,040 | 53,600 | 0.08% | Call option |
| Pathstone Holdings, LLC | $197,537 | 50,650 | 0.07% | Shares |
| Kestra Advisory Services, LLC | $194,263 | 49,811 | 0.07% | Shares |
| RHUMBLINE ADVISERS | $176,133 | 45,164 | 0.06% | Shares |
| WELLS FARGO & COMPANY/MN | $171,924 | 44,083 | 0.06% | Shares |
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, RA Capital Healthcare Fund, L.P. ×2 filings | March 11, 2026 | 9.90% | Amendment | · | SEC |
| Christine Hamilton, Edward Hamilton ×2 filings | Dec. 16, 2022 | · | Initial filing | · | SEC |
| Eddie Joe Sullivan | Sept. 8, 2022 | · | Initial filing | Passive investment | SEC |
| Big Cypress Holdings LLC, Samuel J. Reich ×2 filings | May 27, 2022 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 31 insiders · 16 officers · 16 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Samuel J Reich | CEO | Feb. 3, 2026 A | 219,001 | 0 | 0 | $0 |
| Big Cypress Holdings LLC | CEO and CFO | Jan. 14, 2021 P | 3,047,825 | 0 | 0 | $0 |
| Lucy To | Chief Financial Officer | Feb. 3, 2026 A | · | 0 | 0 | $0 |
| Michael King | CHIEF FINANCIAL OFFICER | Feb. 21, 2024 A | 5,000 | 0 | 0 | $0 |
| Beyer Russell P | Chief Financial Officer | March 14, 2023 A | 15 | 0 | 0 | $0 |
| Eddie Joe Sullivan | PRESIDENT | Feb. 3, 2026 A | 5,232,304 | 0 | 0 | $0 |
| Christoph Lawrence Bausch | CHIEF OPERATING OFFICER | Feb. 3, 2026 A | · | 0 | 0 | $0 |
| Bruce Kipp Erickson | Chief Operating Officer | March 16, 2022 A | · | 0 | 0 | $0 |
| Alexandra Kropotova | CHIEF MEDICAL OFFICER | March 24, 2026 F | 43,296 | 0 | 0 | $0 |
| Melissa Vera Ullerich | Chief Communications Officer | March 16, 2022 A | · | 0 | 0 | $0 |
| Thomas Charles Luke | Chief Medical Officer | March 16, 2022 A | 5,428 | 0 | 0 | $0 |
| Jerry Lynn Pommer | Chief Compliance Officer | March 16, 2022 A | · | 0 | 0 | $0 |
| Frederick Finnegan | Chief Business Officer | March 16, 2022 A | 38,596 | 0 | 0 | $0 |
| Charles Hiram Randall | Chief Strategy Officer | Oct. 22, 2021 A | · | 0 | 0 | $0 |
| Carlos N Carillo | SVP Regulatory Affairs | Oct. 22, 2021 A | · | 0 | 0 | $0 |
| Hua Wu | SVP Research & Product Dev. | Oct. 22, 2021 A | · | 0 | 0 | $0 |
| Rita Jain | Director | Jan. 5, 2026 A | · | 0 | 0 | $0 |
| David Zaccardelli | Director | Jan. 5, 2026 A | · | 0 | 0 | $0 |
| David Link | Director | Dec. 16, 2025 A | · | 0 | 0 | $0 |
| Helen K. Ellias | Director | Dec. 16, 2025 A | 2,857,142 | 0 | 0 | $0 |
| Scott Giberson | Director | Dec. 16, 2025 A | · | 0 | 0 | $0 |
| William James Polvino | Director | Dec. 16, 2025 A | · | 0 | 0 | $0 |
| Jay S Skyler | Director | Dec. 16, 2025 A | · | 0 | 0 | $0 |
| Andrew Moin | Director | Sept. 29, 2025 M | 2,198,457 | 0 | 0 | $0 |
| David Charles Link | Director | July 15, 2024 A | 57,313 | 0 | 0 | $0 |
| Jeffrey G Spragens | Director | July 15, 2024 A | 394,989 | 0 | 0 | $0 |
| Christine E Hamilton | Director | July 15, 2024 A | 3,111,334 | 0 | 0 | $0 |
| Mervyn Turner | Director | Oct. 22, 2021 A | · | 0 | 0 | $0 |
| Ilan Katz | Director | Oct. 13, 2021 P | 1,500 | 0 | 0 | $0 |
| Edward D. Hamilton | 10% owner | Oct. 22, 2021 A | 5,049,351 | 0 | 0 | $0 |
| Erick Lucera | · | Dec. 16, 2025 A | · | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 9 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IWC · iShares Trust | 0.04% | 148,516 SH | Sept. 11, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 251,071 SH | Aug. 19, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.01% | 37,760 SH | Aug. 19, 2026 | Daily |
| RSSL · Global X Funds | 0.01% | 20,748 NS | July 31, 2026 | N-PORT |
| IWM · iShares Trust | 0.00% | 1,033,832 SH | Sept. 11, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 647,886 SH | Aug. 19, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 2,259,593 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 3,897 SH | Aug. 19, 2026 | Daily |
| IWN · iShares Trust | · | 382,504 SH | Sept. 11, 2026 | Daily |
SABS Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 17 analysts
BUY
Median target
$12.00
+302.7%
7 41.2%
Strong Buy
9 52.9%
Buy
1 5.9%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
11 analysts · 2026-10-03Mean target $11.64 +290.5%
← Below all targets
Current price $2.98
Low$6.00
Mean$11.64
High$16.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.